| 词条 | TS-121 |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = | image = | width = | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = By mouth | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = | CAS_supplemental = | class = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | C= | H= | N= | O= | molecular_weight = | SMILES = | StdInChI_Ref = | StdInChI = | StdInChIKey_Ref = | StdInChIKey = | synonyms = TS-1211 }}TS-121 is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[1][2] As of May 2017, it is in phase II clinical trials for this indication.[1][2] See also
References1. ^1 {{cite web | url = http://adisinsight.springer.com/drugs/800041804 | title = TS 121 - AdisInsight | format = | website = | accessdate = }} 2. ^1 {{cite web | url = http://www.taisho-holdings.co.jp/en/ir/finance/development/ | title = New Drug Pipeline - Taisho Pharmaceutical Holdings | format = | website = | accessdate = }} External links
4 : Antidepressants|Drugs with undisclosed chemical structures|Experimental drugs|Vasopressin receptor antagonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。